SCHEMBL23705472

SCHEMBL23705472

COC(=O)c1ccn(CC#N)n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
MAPK1 P28482 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
AR P10275 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19253464 0.85 CYP1A2 (0.45) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL10133288 0.80 ALDH1A1 (0.63) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL31537093 0.80 SMN1; SMN2 (0.48) KMT2ANPC1RAB9AMEN1TDP1
SCHEMBL4796110 0.79 ALDH1A1 (0.36) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL25786633 0.79 RAB9A (0.57) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL864467 0.78 KMT2A (0.59) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL26910772 0.78 NPC1 (0.56) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL20156306 0.76 RAB9A (0.55) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL10026496 0.75 KMT2A (0.64) KMT2ANPC1RAB9AMEN1POLB
SCHEMBL28851114 0.75 NPC1 (0.53) KMT2ANPC1RAB9AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230121497-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-04-20 US disclosed
EP-4096668-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155264-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121497-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KMT2A 792/4885NPC1 138/4885RAB9A 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.